SG11201809620UA - The contorsbody - a single chain target binder - Google Patents

The contorsbody - a single chain target binder

Info

Publication number
SG11201809620UA
SG11201809620UA SG11201809620UA SG11201809620UA SG11201809620UA SG 11201809620U A SG11201809620U A SG 11201809620UA SG 11201809620U A SG11201809620U A SG 11201809620UA SG 11201809620U A SG11201809620U A SG 11201809620UA SG 11201809620U A SG11201809620U A SG 11201809620UA
Authority
SG
Singapore
Prior art keywords
de
part
il
international
ch
Prior art date
Application number
SG11201809620UA
Inventor
Stefan Dengl
Guy Georges
Friederike Hesse
Sabine Imhof-Jung
Josef Platzer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP16167920 priority Critical
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to PCT/EP2017/060354 priority patent/WO2017191101A1/en
Publication of SG11201809620UA publication Critical patent/SG11201809620UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111011111111101 IIIIIIIIIIIIIIIIIII101110111111110111111011111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/191101 Al 09 November 2017 (09.11.2017) WIP0 I PCT (51) International Patent Classification: Egenhofenstr. 26 b, 82152 Planegg (DE). PLATZER, C07K 16/00 (2006.01) Josef; Schlierseeweg 9, 82538 Geretsried (DE). (21) International Application Number: (74) Agent: SKOLAUT, Alexander et al.; Roche Diagnostics PCT/EP2017/060354 GmbH, Patent Department (LPP 6164), P.O.Box 11 52, 82372 Penzberg (DE). (22) International Filing Date: 02 May 2017 (02.05.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 16167920.4 02 May 2016 (02.05.2016) EP KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (71) Applicant (for all designated States except US): F. HOFF- MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 124, 4070 Basel (CH). SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Great Notch, 150 Clove Road, 8th Floor, (84) Designated States (unless otherwise indicated, for every Little Falls, New Jersey 07424 (US). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: DENGL, Stefan; Schleissheimer Str. 44a, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 80333 Muenchen (DE). GEORGES, Guy; Am Berggraben = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — 11, 82392 Habach (DE). HESSE, Friederike; Ganghofer- EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = str. 23, 80339 Muenchen (DE). IMHOF-JUNG, Sabine; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = = = (54) Title: — _ = = = = THE CONTORSBODY - A SINGLE CHAIN TARGET BINDER (57) : Herein is reported a circular fusion polypeptide comprising a first part of a binding domain, a second part of a Figure 2A binding domain and a spacer domain, wherein the spacer domain is a polypeptide and comprises at least 25 amino acid residues, the first part of the binding domain is a polypeptide and is fused via a first linker to the N- terminus of the spacer domain, the second part of the binding domain is a polypeptide and is fused via a second linker to the C-terminus of the spacer domain, the _ = . . _ . . . first part of the binding domain and the second part of the binding = domain are associated with each other and form a binding site = c - — that specifically binds to a target. = . .. - .-- Il Ill . © Il ii Il C:r Il Ir ... ' Il © ei C [Continued on next page] WO 2017/191101 Al MIDEDIMOMOIDEIROIDEMOMOIHMOVOIDIROIIMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with amended claims (Art. 19(1)) — with sequence listing part of description (Rule 5.2(a))
SG11201809620UA 2016-05-02 2017-05-02 The contorsbody - a single chain target binder SG11201809620UA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP16167920 2016-05-02
PCT/EP2017/060354 WO2017191101A1 (en) 2016-05-02 2017-05-02 The contorsbody - a single chain target binder

Publications (1)

Publication Number Publication Date
SG11201809620UA true SG11201809620UA (en) 2018-11-29

Family

ID=56008478

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809620UA SG11201809620UA (en) 2016-05-02 2017-05-02 The contorsbody - a single chain target binder

Country Status (11)

Country Link
EP (1) EP3452502A1 (en)
KR (1) KR20190003678A (en)
CN (1) CN109071635A (en)
AU (1) AU2017259869A1 (en)
BR (1) BR112018069890A2 (en)
CA (1) CA3019524A1 (en)
CL (1) CL2018003007A1 (en)
CR (1) CR20180509A (en)
PE (1) PE18902018A1 (en)
SG (1) SG11201809620UA (en)
WO (1) WO2017191101A1 (en)

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334351D1 (en) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetic binding protein for tumor markers
RU2139731C1 (en) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Methods of treatment, antibodies, hybridoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AT419009T (en) 1997-10-31 2009-01-15 Genentech Inc Methods and compositions consisting of glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (en) 1997-12-05 2004-06-15 Scripps Research Inst Method for the production and humanisation of a mouse monoclonal antibody
JP2002510481A (en) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
PL209786B1 (en) 1999-01-15 2011-10-31 Genentech Inc. Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2418360T3 (en) 1999-04-09 2013-08-13 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of a molecule immunofunctional
DE60022369T2 (en) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy A process for the regulation of transcription of foreign genes in the presence of nitrogen
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
JP2003516755A (en) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド Shotgun scan, i.e. the combination method for mapping functional protein epitope
WO2001049698A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2314686B1 (en) 2000-10-06 2017-07-05 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1354034T3 (en) 2000-11-30 2008-03-25 Medarex Inc Transgenic transchromosomale rodents to produce human antibodies
CN1294148C (en) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 Single-stranded cyctic trispecific antibody
HU0700103A3 (en) 2001-08-03 2012-09-28 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7139665B2 (en) 2002-02-27 2006-11-21 California Institute Of Technology Computational method for designing enzymes for incorporation of non natural amino acids into proteins
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition
MXPA04009924A (en) 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Cells with modified genome.
EP1500698B1 (en) 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP4753578B2 (en) 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
EP1675620A4 (en) 2003-10-09 2006-12-27 Ambrx Inc Polymer derivatives
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF a1,6-FUCOSYLTRANSFERASE
WO2005044859A2 (en) 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JPWO2005053742A1 (en) 2003-12-04 2007-06-28 協和醗酵工業株式会社 Pharmaceutical comprising the antibody compositions
BRPI0507118A (en) 2004-02-02 2007-06-19 Ambrix Inc polypeptide modified human interferon and their uses
RU2386638C2 (en) 2004-03-31 2010-04-20 Дженентек, Инк. Humanised anti-tgf-beta-antibody
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ES2403055T3 (en) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anti-P-selectin
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
BRPI0516284A (en) 2004-09-23 2008-09-02 Genentech Inc Built antibody with cysteine, a method to select antibodies, conjugates of antibody-drug, pharmaceutical composition, method of killing or inhibiting tumor cell proliferation, methods of inhibiting cell proliferation and tumor cell growth, article of manufacture and method to produce a compound
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
TWI544076B (en) 2005-03-31 2016-08-01 Chugai Pharmaceutical Co Ltd
WO2007048022A2 (en) 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AR060070A1 (en) 2006-03-24 2008-05-21 Merck Patent Gmbh heterodimeric protein domains obtained by engineering
AR060871A1 (en) 2006-05-09 2008-07-16 Genentech Inc Union of polypeptides with optimized supercontigos
TW200813086A (en) 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
RU2487888C2 (en) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Single-chain multivalent binding proteins with effector function
JP2009541275A (en) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー/エス Production of bispecific antibody
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司;群创光电股份有限公司 Liquid crystal panel drive device and its drive method
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2012525149A (en) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods for making heteromultimeric molecules
ES2592385T3 (en) 2009-12-29 2016-11-29 Aptevo Research And Development Llc Heterodimers binding proteins and uses thereof
AR080793A1 (en) * 2010-03-26 2012-05-09 Roche Glycart Ag bispecific antibodies
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN108341868A (en) 2010-11-05 2018-07-31 酵活有限公司 Stable heterodimeric antibody design with mutations in the Fc domain
AU2012355415B2 (en) 2011-12-20 2017-07-06 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
MX360110B (en) 2012-04-20 2018-10-23 Merus N V Methods and means for the production of ig-like molecules.
CA2896359A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
AR106188A1 (en) 2015-10-01 2017-12-20 F Hoffmann-La Roche Ag Humanized anti-human CD19 antibodies and methods of use

Also Published As

Publication number Publication date
CR20180509A (en) 2019-02-15
BR112018069890A2 (en) 2019-02-05
PE18902018A1 (en) 2018-12-11
AU2017259869A1 (en) 2018-09-27
KR20190003678A (en) 2019-01-09
WO2017191101A1 (en) 2017-11-09
EP3452502A1 (en) 2019-03-13
CN109071635A (en) 2018-12-21
CL2018003007A1 (en) 2019-02-08
CA3019524A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
SG11201407802WA (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201804807VA (en) Computer architecture and method for modifying data intake parameters based on a predictive model
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201408279QA (en) Social sharing of security information in a group
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201407564TA (en) St2 antigen binding proteins
SG11201407644UA (en) Methods for making fully human bispecific antibodies using a common light chain
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201808907PA (en) Inhibitors of activin receptor-like kinase
SG11201807091WA (en) E-vaping device cartridge with internal conductive element
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201807771UA (en) Multiple dispersion generator e-vaping device
SG11201406977TA (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201803697SA (en) Method for the economic manufacturing of metallic parts
SG11201804765UA (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
SG11201807389XA (en) System and method for beam management
SG11201406963RA (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201806404SA (en) Systems and methods for storing and sharing transactional data using distributed computer systems
SG11201803717VA (en) Method and system for shared transport